Targeting epigenetic enzymes for drug discovery

被引：85

作者：

Copeland, Robert A. ^{[1
]}

Olhava, Edward J. ^{[1
]}

Scott, Margaret Porter ^{[1
]}

机构：

[1] Epizyme Inc, Cambridge, MA 02139 USA

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 2010年 / 14卷 / 04期

关键词：

HISTONE; METHYLTRANSFERASES; METHYLATION; KINASE; ROLES; DNA;

D O I：

10.1016/j.cbpa.2010.06.174

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Epigenetic control of gene transcription is the result of enzyme-mediated covalent modifications of promoter-region DNA sites and of histone proteins around which chromosomal DNA is wound. Many of the enzymes that mediate these epigenetic reactions are dysregulated in human diseases. Small molecule inhibitors against two classes of these enzymes have been approved for use in patients: DNA methyltransferase (DNMT) inhibitors and histone deacetylase inhibitors. Other classes of epigenetic enzymes have been demonstrated to have strong disease association and are currently being targeted for small molecule inhibition. In this article we review these enzymes and chemical biology approaches aimed at discovering small molecule inhibitors against them for therapeutic use.

引用

页码：505 / 510

页数：6

共 38 条

[1] DNA methylation and gene silencing in cancer [J].